ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your brain tumor is an astrocytoma (grade 2–4) or oligodendroglioma (grade 2–3) that is growing again after prior chemo (temozolomide and/or lomustine) and sometimes radiation
- Your tumor has a confirmed IDH1 or IDH2 mutation from tumor testing
- Your MRI can be done with contrast dye (gadolinium) and steroid dose is stable or lower before the first MRI
- You must have recovered enough from past treatment side effects and be out of treatment for required time periods
- You must be able to swallow pills and be well enough to travel for study visits (Karnofsky score 60+; life expectancy over 3 months)
- You cannot have certain immune problems, lung inflammation, recent immune-targeting drugs, or other major medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy (L19TNF plus a chemotherapy drug like temozolomide or lomustine) for people whose IDH-mutant astrocytoma or oligodendroglioma has returned after earlier chemotherapy. The goal is to see if this combination slows tumor growth safely.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.